

Non *in vivo* skin sensitization strategy under REACH in practice: hurdles that need attention to minimize the need for *in vivo* testing

S.M.G.J. Pelgrom¹, H.M. Barentsen¹, S.U. Jonis¹, W.M.A. Westerink², J.C.W. Rijk², J.J.C. Paulussen¹

¹Regulatory Affairs, Charles River Laboratories, 's-Hertogenbosch, The Netherlands.

²Discovery, Charles River Laboratories, 's-Hertogenbosch, The Netherlands.




1 Introduction

Since October 2016 *in vivo* testing for skin sensitization has been replaced by non-animal tests for the registration of industrial chemicals under REACH (Commission Regulation (EU) 2016/1688 and 2017/706). A comprehensive testing strategy has been implemented, as no single non *in vivo* test fulfils the requirements for the toxicity endpoint skin sensitization. *In vivo* testing for skin sensitizing properties is permitted as a last resort only.

With the amended requirements, skin sensitizing potency needs to be determined for skin sensitizing substances (Cat 1A *versus* 1B), in order to identify extreme sensitizers needing a specific concentration limit for use in mixtures. There is currently no standardized way to assess potency with the available and accepted non *in vivo* methods.

Charles River Laboratories proposes tiered strategies for both mono/multi-constituents and for UVCB's/metal containing substances, and presents the results from 33 chemicals which have been tested for their skin sensitizing properties with non *in vivo* tests. Results obtained with the currently available and regulatory accepted non *in vivo* tests do not always permit a definite conclusion on skin sensitizing properties; moreover, as the present non *in vivo* tests do not include information on skin sensitizing potency, *in vivo* testing is still needed for a substantial number of substances.


2 AOP skin sensitization and tests



QSAR Model DEREK NEXUS (Knowledge-based):
No alerts fired is related to a negative prediction. The database includes information on metabolism and on potency (EC3 value). Together with the study results, this information may give more body to the weight of evidence (WoE).


Figure 1: Skin sensitization Adverse Outcome Pathway based on (ENV/JM/MONO(2012)10/PART1 and OECD tests

3 Proposed Test Strategy for a) Mono/multi-constituents and for b) UVCBs/'metals'



b UVCBs, 'metals': tests are available for key event 2 (ARE-Nrf2) and key event 3 U-SENS™ (MUSST)/h-CLAT, WoE and potency

4 Results



Test results

A significant number of tests gave inconclusive results (testing up to and including highest required test concentration not possible).

For UVCBs and 'metals' only two non *in vivo* tests are available yet, resulting generally in *in vivo* testing

In the absence of reliable information on skin sensitizing potency, positive substances still need to be tested *in vivo*.

5 Considerations and Conclusion

Hurdles that need attention:

- Low solubility of substance results in inconclusive results, as not tested up to and including the highest concentration required according to Guidelines
- High partition coefficient of substance (result is comparable to low solubility)
- High molecular weight (no dermal absorption)
- UVCB or 'metal': DPRA and DEREK not possible.; only two acceptable non *in vivo* tests available (two out of three tests not possible)
- The currently available non-animal test methods have no or limited metabolic capacity; this may result in false negative results
- Results key event 1 not crucial for overall outcome (a)
- No *in vitro* potency test is available yet that is acceptable for regulatory and classification purposes.

At this moment, non *in vivo* tests for skin sensitization cannot replace the LLNA completely (due to equivocal results, lack of potency), nor is it accepted yet by all other legal frameworks. Further development/refinement of alternative testing as well as reliable and acceptable *in vitro* skin sensitizing potency tests are required. Currently two potency tests are being validated: *GARDskin/SENS-IS*, which potentially could replace animal testing significantly.

(a) Barentsen HM, Jonis SU, Pelgrom SMGJ (*in prep*)
REACH alternative testing strategy for skin sensitization in practice; fact or fiction?